LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genotyping Helps Avoid Needless Bone Marrow Biopsies in African-Americans

By LabMedica International staff writers
Posted on 13 Jul 2021
Image: A normal bone marrow biopsy: Note the presence of an eosinophilic myelocyte, a basophilic myelocyte, and a plasma cell. There is an association between a common, benign genotype and unnecessary bone marrow biopsies among African-American patients (Photo courtesy of University of Utah School of Medicine)
Image: A normal bone marrow biopsy: Note the presence of an eosinophilic myelocyte, a basophilic myelocyte, and a plasma cell. There is an association between a common, benign genotype and unnecessary bone marrow biopsies among African-American patients (Photo courtesy of University of Utah School of Medicine)
Bone marrow biopsies may be used unnecessarily in some African American individuals who are genetically predisposed to having relatively low white blood cell counts.

The rs2814778 genotype is within the DARC gene, which encodes the Duffy blood group antigen. This single nucleotide polymorphism (SNP) shows an almost perfectly fixed difference in frequency between Europeans and those with African ancestry. (One exception appears to be a certain population of Czech gypsies, and certain non-Ashkenazi Jewish populations.)

A team of medical scientists led by the Vanderbilt University Medical Center group (Nashville, TN, USA) carried out a genetic association study, among 399 African- American individuals who underwent a bone marrow biopsy as part of routine clinical care at three medical centers, from January 1, 1998, to December 31, 2020. The rs2814778-CC genotype was highly prevalent when the biopsy was performed to evaluate isolated low WBC counts. In the absence of another cell type abnormality, these biopsies very rarely identified a hematologic abnormality.

The team reported that the rs2814778-CC genotype, previously linked to low white blood cell counts, was present in some 67% of the individuals who were referred for bone marrow biopsies based on their medical history, beyond low white blood cell counts alone. In contrast, the team noted that the rs2814778-CC genotype turned up in all but one of the 35 patients who underwent bone marrow biopsies solely based on lower-than-usual white blood cell counts. Those results hinted that testing may have been unnecessary in this small subset of patients, particularly since 97% of them had normal biopsy results, compared to 55% in the subset of 243 African American patients who did not carry the rs2814778-CC genotype.

The study found that white blood cell counts may be low due to an rs2814778-CC variant in the promoter of the atypical chemokine receptor 1-coding gene (ACKR1). Among 399 individuals who underwent a bone marrow biopsy (BMB) (mean ± SD, age, 41.8 ± 22.5years, 234 [59%] female), 277 (69%) had the CC genotype. A total of 35 patients (9%) had clinical histories of isolated low WBC counts, and 364 (91%) had other histories. Of those with a clinical history of isolated low WBC count, 34 of 35 (97%) had the CC genotype versus 243 of 364 (67%) of those without a low WBC count history. Among those with the CC genotype, 33 of 34 (97%) had normal results for biopsies performed for isolated low WBC counts compared with 134 of 243 individuals (55%) with biopsies performed for other histories.

Jonathan D. Mosley, MD, PhD, an Assistant Professor and a senior author of the study, said, “We've essentially created this racial health disparity by not fully considering how genetic variation affects white blood cell levels. Our study supports genotyping African Americans before performing a bone marrow biopsy for the indication of isolated low white blood cell counts.”

The authors concluded that in this genetic association study, among patients of African American race who had a BMB with a clinical history of isolated low WBC counts, the rs2814778-CC genotype was highly prevalent, and 97% of these BMBs identified no hematologic abnormality. Accounting for the rs2814778-CC genotype in clinical decision-making could avoid unnecessary BMB procedures. The study was published on June 28, 2021 in the journal JAMA Internal Medicine.

Related Links:
Vanderbilt University Medical Center group

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gold Member
Hybrid Pipette
SWITCH

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more